Steve Jurvetson
Partner @ Threshold
San Francisco, United States
Steve Jurvetson is a Series A investor at Threshold in San Francisco focused on Software and Biotechnology. Steve Jurvetson fosters companies at the forefront of technology. He looks for unconventional companies in deep learning, commercial space, synthetic biology, genomics, robotics, and sustainable transportation—purpose-driven companies that will transform massive industries.His current board responsibilities include D-Wave, Memphis Meats,Mythic, Planet, SpaceX, Synthetic Genomics, and Tesla (NASDAQ: TSLA). He was the founding VC investor in Hotmail (Microsoft), Interwoven (NASDAQ: IWOV), Kana (NASDAQ: KANA), and NeoPhotonics (NYSE: NPTN). Steve was also the first VC investor and board member at deep learning company Nervana, acquired by Intel in 2016. He always has a passion for the cutting edge of technology and the frontiers of the unknown. Steve has BS and MS degrees in electrical engineering from Stanford, and he finished his undergrad studies in 2.5 years, graduating number one in his class. He went on to earn an MBA from the Stanford Graduate School of Business and was named an Arjay Miller Scholar. He then worked at leading companies like HP, Apple, NeXT Software, and Bain & Company.In 2017, Steve received the Visionary Award from SV Forum for his role in fostering the spirit of entrepreneurship in Silicon Valley. In 2016, President Barack Obama announced Steve's position as a Presidential Ambassador for Global Entrepreneurship at the Seventh Global Entrepreneurship Summit at Stanford University. Steve has also been honored as a Young Global Leader by the World Economic Forum, and as the Venture Capitalist of the Year by Deloitte. He was also chosen by the San Francisco Chronicle and San Francisco Examiner as one of "the ten people expected to have the greatest impact on the Bay Area in the early part of the 21st century." Forbes has recognized Steve several times on the Midas List, and named him one of "Tech's Best Venture Investors."
- Total investments:
- 85
- Last investment:
- Lead investor:
- 31%
Last updated:
For AI agents: llms.txt
Industries Steve Jurvetson invests in
Stages Steve Jurvetson invests in
Countries Steve Jurvetson invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $2.7M–$20M
- Series A
- $2M–$47M
- Series B
- $6M–$120M
Investment Focus
Industry
- Software 13 (15%)
- Biotechnology 13 (15%)
- Manufacturing 8 (9%)
- Medical 5 (6%)
- Hardware 4 (5%)
Stage
- Series A 22 (26%)
- Series B 12 (14%)
- Seed 9 (11%)
- Series C 8 (9%)
- Funding Round 8 (9%)
Country
- United States 40 (47%)
- Canada 2 (2%)
- India 1 (1%)
- Estonia 1 (1%)
- Germany 1 (1%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| We are a Boston-based startup using machine learning, AI, and audio technologies to create safer & more inclusive voice chat experiences with ToxMod | $25M / Venture - Series Unknown / Sep 28, 2026 | ||
| Red Metals is a next-generation copper manufacturing startup building America's first domestic high-conductivity copper rod production facility in Charleston, South Carolina. | $10M / Seed / Jun 04, 2026 | ||
| Pumpkinseed allows for high-speed readings of biological bits. | $20M / Series A / May 05, 2026 | ||
| Mojo Vision is a developer of augmented reality products and platforms intended to invent the future of computing. The company has developed a smart contact lens with a built-in display that gives timely information without interrupting the focus and delivers immediate, powerful, and relevant information without the intrusions of today'smobile devices, enabling users to connect with others at a glance, anytime, anywhere handsfree.Mojo Vision was founded in 2015 and headquartered in Saratoga, California. | $17.5M / Venture - Series Unknown / Mar 25, 2026 | ||
| ZaiNar is a technology that can track the real-time location of anything. The company's platform uses radio signals including cellphones, IoT sensors, and chipless RFID tags for positioning that is far more scalable, cost-effective and accurate than existing alternatives, enabling enterprises to track locations with over 200 meters range andsub-meter accuracy. | $100M / Series B / Feb 19, 2026 | ||
| Mythic is a diverse group of individuals focused on developing cutting-edge analog matrix processors based on our unique analog compute-in-memory. Their products are the M1076 Analog Matrix Processor, MP10304 Quad-AMP PCIe Card, and MM1076 M.2 M Key Card. They offer AI solutions, from the data center to the edge device. | $125M / Series D / Dec 17, 2025 | ||
| Faeth Therapeutics is a data-driven, evidence-based company that specializes in mechanistic understanding of the way that dietary nutrients influence tumor growth and cancer treatment. It fully focuses on matching specific diets with tumor genotypes and treatment regimens to improve the outcomes of cancer therapy.The company was founded totranslate breakthrough discoveries, made by cancer research laboratories, into clinical practice. Its founding team includes some of the industry’s preeminent researchers and clinicians. | $25M / Series A / Oct 20, 2025 | ||
| We harness the power of fermentation to make versatile mycoprotein ingredients for food companies to use as the basis of their blended and fully animal-free meats.We’re laser-focused on solving the meat sustainability crisis our planet faces. By harnessing the power of fermentation, we’re working to enable our species to enjoy all the meat wecrave, but with a tiny sliver of the footprint we currently have on the planet and animals. In short, we aspire to revolutionize the meat industry by creating a new and better way to make meat. It will be delicious; it will be satisfying; and it will be affordable. And it will create a cleaner, greener planet for all of us to enjoy. | $31M / Series A / Aug 19, 2025 | ||
| Gameto is a biotechnology company whose mission is to redefine female reproductive health by developing therapies that improve lives.Women’s health is a vastly underserved therapeutic area. Most conditions have few treatment options, and those available often cause frequent complications and offer limited clinical benefit. Gameto aims to changethat.Gameto is committed to using cutting-edge scientific advances to deliver better solutions to patients. Using cellular engineering, they have developed a platform to produce female reproductive cell lines. They use proprietary combinations of transcription factors to reprogram hiPSCs into engineered ovarian and endometrium cell lines that mimic the functions of endogenous cells, producing and responding to all hormones. Their team of cellular engineers is using this platform to advance a portfolio of cellular therapeutics for female reproductive diseases. Gameto's first program, Fertilo, is a therapeutic for IVF and egg freezing, aiming to make the process shorter, safer and more effective. Additional applications of our platform include, an organoid of the female reproductive system, Deovo, and a cell-based therapeutic to ameliorate the health consequences of primary ovarian insufficiency and menopause, Ameno. | $44M / Series C / Aug 12, 2025 | ||
| Centivax is a healthcare-based agency that provides biotechnology, pharmaceutical, medical device manufacturing, and therapeutic services. | $45M / Series A / Jul 08, 2025 | ||
| See all 85 investments → | |||
Co-Investors
About Threshold
Threshold is an early-stage venture capital firm that focuses on a high-conviction investment strategy. The firm partners with entrepreneurs to build innovative consumer, enterprise, and healthcare technology companies.
Threshold Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Bill Bryant
General Partner
|
|||
|
Maryanna Saenkohas
Senior Associate
|
|||
Andreas Stavropoulos
Partner
|
|||
Arpit Mittal
Investor
|
|||
Carol Wentworth
Marketing partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Steve Jurvetson invest in?
Steve Jurvetson invests primarily in Software, Biotechnology and Manufacturing startups, most often at Series A and Series B stage. Most of the 85 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Steve Jurvetson invest in?
Steve Jurvetson typically joins rounds of $2.7M–$20M at Seed, $2M–$47M at Series A and $6M–$120M at Series B. These are whole funding-round sizes, not Steve Jurvetson's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Steve Jurvetson took part in.
How do I contact Steve Jurvetson?
Public channels for Steve Jurvetson include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Steve Jurvetson last invest?
The most recent investment recorded for Steve Jurvetson closed in Sep 2026. Shizune tracks 85 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
